Quizartinib study for people with severe liver problems
Treatments studied
Part of Digestive system clinical trials.
This trial tests how the body processes quizartinib when the liver is severely impaired. It helps doctors understand if the dose needs to be adjusted for patients with liver issues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your body mass index (BMI) must be between 18 and 37, and you must weigh at least 88 pounds (40 kg).
- If you are a woman who can get pregnant, you need to use effective birth control or be sterile or past menopause.
- If you are a man, you must use effective birth control and not donate sperm during the study and for a period afterward.
- You cannot have certain liver conditions like primary biliary cirrhosis, primary sclerosing cholangitis, or Gilbert's syndrome.
- You must not have had stomach or bowel surgery that could affect how oral medication is absorbed (minor surgeries like appendix removal are okay).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how a drug called Zanzalintinib acts in people with moderate liver impairment compared to healthy volunteers. It aims to ensure the drug is safe and at the right dose for people with liver issues.
This Phase 1 study measures how tasurgratinib (E7090) and its breakdown product move through the body in people with mild or moderate liver impairment. It aims to understand appropriate dosing and safety considerations for liver impairment.
This trial tests how a new medicine, BI 1291583, enters the blood in people who have different levels of liver function (from normal to mild, moderate, or severe liver problems). It helps doctors understand if the dose needs to be adjusted for liver health.
This research study tests how two experimental drugs (AZD9550 and AZD6234) work in people with different levels of liver function. The goal is to understand whether liver disease changes how the body processes these medications, which may help doctors safely treat patients with liver problems in the future.
This study looks at how the medicine PF-07328948 is processed by people with different levels of liver function. It includes both healthy people and those with stable liver disease (classified as mild, moderate, or severe). The goal is to see if the liver condition affects how the drug works in the body.
This trial tests a combination of anti-leukemia drugs (including quizartinib) together with chemotherapy for people with acute myeloid leukemia (AML), a rare mixed-type leukemia, or high-risk myelodysplastic syndrome (MDS). It may help by trying to better control cancer in people whose disease is newly diagnosed or has returned/not responded to prior treatment.
Hear when a new Hepatic Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.